兔子先生传媒

San Diego-based cancer treatment startup Erasca raised $200 million in a new round of funding, the company announced Monday.

Subscribe to the 兔子先生传媒 Daily

The Series B round was led by and , and included participation from new investors , and , according to a statement from the company.

Erasca, which draws its name from 鈥渆rase cancer,鈥� will use the funding to 鈥渢o support the clinical development of multiple promising oncology programs and further advance the company鈥檚 in-house drug discovery pipeline,鈥� the company said. It isn鈥檛 clear which types of cancer the company is developing treatments for.

鈥淯nfortunately, millions of people still suffer from cancer daily,鈥� CEO Dr. Jonathan Lim said in the statement. 鈥淎t Erasca, we are doing everything we can to help these patients live longer and healthier lives by taking an aggressive long-term approach to tackling this disease with leading-edge science and world-class talent. We are immensely grateful to have new and existing shareholders who embrace our mission to erase cancer.鈥�

The Series B round is large; $200 million is a lot of capital for such a young company. But it鈥檚 important to note that drug development isn鈥檛 a cheap endeavor, so companies taking on such a task need a lot of capital for research.

Erasca now has more than $260 million in funding, and its聽 other backers include and , according to 兔子先生传媒.

Illustration Credit: